Sumitomo Pharma Co (STU:DPM) Marketable Securities: €29 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:DPM Sumitomo Pharma Co Ltd STU:DPM
71 GF Score
Price €6.46
GF Value €4.66
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sumitomo Pharma Co Marketable Securities?

Sumitomo Pharma Co STU:DPM -5.07% 71 Marketable Securities is €29 Mil as of Mar. 2026. GuruFocus rates STU:DPM with a GF Score™ of 71/100 and a GF Value™ of €4.66 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Sumitomo Pharma Co's Marketable Securities for the quarter that ended in Mar. 2026 was €29 Mil.

Sumitomo Pharma Co's annual Marketable Securities increased from Mar. 2024 (€44 Mil) to Mar. 2025 (€105 Mil) but then declined from Mar. 2025 (€105 Mil) to Mar. 2026 (€29 Mil).

Sumitomo Pharma Co  (STU:DPM) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Sumitomo Pharma Co Marketable Securities Related Terms

Sumitomo Pharma Co Marketable Securities Historical Data

* Premium members only.

The historical data trend for Sumitomo Pharma Co's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sumitomo Pharma Co Marketable Securities Chart

Sumitomo Pharma Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 272.57 140.97 43.51 104.50 29.04

Sumitomo Pharma Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 104.50 95.27 55.58 54.81 29.04
STU:DPM
71GF Score
Sumitomo Pharma Co Ltd STU:DPM
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sumitomo Pharma Co Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €29 Mil mean?
Sumitomo Pharma Co (STU:DPM) has a Marketable Securities of €29 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Sumitomo Pharma Co and its competitors.
Is Sumitomo Pharma Co's Marketable Securities too high?
Sumitomo Pharma Co's current Marketable Securities is €29 Mil. Overall, Sumitomo Pharma Co has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sumitomo Pharma Co's Marketable Securities compare to ZTS?
Sumitomo Pharma Co's Marketable Securities of €29 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Sumitomo Pharma Co and its competitors. Sumitomo Pharma Co's current Marketable Securities is €29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sumitomo Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Sumitomo Pharma Co (STU:DPM) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.66, compared to a current price of €6.46 — trading 38.6% above its estimated fair value. The current Marketable Securities is €29 Mil. Sumitomo Pharma Co's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Sumitomo Pharma Co (STU:DPM), the current Marketable Securities is €29 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sumitomo Pharma Co (STU:DPM) Overvalued in 2026?

Based on GuruFocus' analysis, Sumitomo Pharma Co stock appears to be overvalued. The current stock price of €6.46 is trading 38.6% above its estimated GF Value™ of €4.66. GuruFocus considers Sumitomo Pharma Co to be Significantly Overvalued.

Key valuation signals for STU:DPM:

  • Marketable Securities: €29 Mil
  • GF Value™: €4.66 vs. price of €6.46 (38.6% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the STU:DPM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sumitomo Pharma Co Business Description

Address 6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
71GF Score

Get the complete analysis for STU:DPM

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.46
Price
€4.66
GF Value